Virax Biolabs Group (Virax Biolabs Group) Total Stockholders Equity : $6.33 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Total Stockholders Equity?

Virax Biolabs Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $6.33 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Virax Biolabs Group's Book Value per Share for the quarter that ended in Sep. 2023 was $3.50. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Virax Biolabs Group's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.03.

Virax Biolabs Group Total Stockholders Equity Historical Data

The historical data trend for Virax Biolabs Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Total Stockholders Equity Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

-1.06

-0.65

-0.98

9.13

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial			-0.80	-0.98	4.39	9.13	6.33

Virax Biolabs Group (NAS:VRAX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Virax Biolabs Group's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.333	-	0)	/	1.81154
	=	3.50

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Virax Biolabs Group's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.05	+	0.132)	/	6.333
	=	0.03

Virax Biolabs Group Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.